ARTICLE | Clinical News
Exjade deferasirox regulatory update
January 7, 2013 8:00 AM UTC
On Dec. 21, 2012, Novartis said that the European Commission approved a label expansion for Exjade deferasirox to treat chronic iron overload requiring chelation therapy when deferoxamine therapy is c...